Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbio CoROCO:4128 -0.34%55 Receivables Turnover is 10.65 as of Mar. 2026. GuruFocus rates ROCO:4128 with a GF Score™ of 55/100 and a GF Value™ of NT$44.55 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,942 Consumer Packaged Goods companies, Microbio Co ranks better than 91.61% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Microbio Co's Revenue for the
three
months ended in Mar. 2026 was NT$502 Mil. Microbio Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$47 Mil.
Hence, Microbio Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 10.65.
Microbio Co (ROCO:4128) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Microbio Co Receivables Turnover Related Terms
Microbio Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Microbio Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4128 vs KHC, GIS: Receivables Turnover Comparison
For the Packaged Foods subindustry, Microbio Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbio Co Receivables Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Microbio Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Microbio Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbio Co (ROCO:4128) has a Receivables Turnover of 10.65 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Microbio Co and its competitors. According to the industry distribution chart, Microbio Co ranks #163 out of 1942 companies in the Consumer Packaged Goods industry, placing it in the top 8.4%.
Is Microbio Co's Receivables Turnover too high?
Microbio Co's current Receivables Turnover is 10.65. The Consumer Packaged Goods industry median Receivables Turnover is 9.38. Microbio Co's value of 10.65 is 13.6% above this industry median. Based on the distribution chart, Microbio Co ranks #163 out of 1942 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Microbio Co has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Microbio Co's Receivables Turnover compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Microbio Co ranks #163 out of 1942 companies for Receivables Turnover. This places Microbio Co in the top 8% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 9.38. Microbio Co's value of 10.65 is 13.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Consumer Packaged Goods company?
The median Receivables Turnover among Consumer Packaged Goods companies is 9.38, based on 1,942 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microbio Co's current Receivables Turnover of 10.65 is 13.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Microbio Co and its competitors. For the Consumer Packaged Goods industry, the median Receivables Turnover is 9.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbio Co's current Receivables Turnover is 10.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbio Co stock overvalued right now?
Based on GuruFocus' analysis, Microbio Co (ROCO:4128) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$44.55, compared to a current price of NT$14.65 — trading 67.1% below its estimated fair value. The current Receivables Turnover is 10.65 and 13.6% above the Consumer Packaged Goods industry median of 9.38. Microbio Co's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Microbio Co (ROCO:4128), the current Receivables Turnover is 10.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbio Co (ROCO:4128) Overvalued in 2026?
Based on GuruFocus' analysis, Microbio Co stock appears to be undervalued.
The current stock price of NT$14.65 is trading 67.1% below its estimated GF Value™ of NT$44.55.
GuruFocus considers Microbio Co to be Significantly Undervalued.
Key valuation signals for ROCO:4128:
Receivables Turnover: 10.65
GF Value™: NT$44.55 vs. price of NT$14.65 (67.1% below fair value)
Industry Position: 13.6% above the Consumer Packaged Goods median (#163 of 1942)
No single metric tells the full story. See the ROCO:4128 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbio Co Ltd is engaged in the research and development, manufacturing, and trading of biotech drugs and dietary supplements. Its drug portfolio includes MS-20, a mixture of soybean fermentation metabolites, which improves fatigue and loss of appetite in cancer patients undergoing chemotherapy. In addition, the company also offers Lee Herb series of herbal essence drinks, Tien Chun Bao oral solutions, Herbiron oral solutions for iron deficiency, and other pharmaceutical and organic products. The company generates revenue from biotech drug research and development and the sale of dietary supplements. The majority of its revenue is generated from the sale of its dietary supplements.
55GF Score
Get the complete analysis for ROCO:4128
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4128 has been successfully added to your 
